V

Vanda Pharmaceuticals
D

VNDA

5.63000
USD
-0.205
(-3.51%)
مغلق
حجم التداول
25,636
الربح لكل سهم
0
العائد الربحي
0
P/E
-25
حجم السوق
282,122,671
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    4.380
    (2.36%)
    189.700 USD
    AMGN
    2.78
    (0.84%)
    335.22 USD
    B
    BIIB
    -2.500
    (-1.17%)
    210.710 USD
    B
    BMRN
    0.270
    (0.32%)
    84.620 USD
    GILD
    0.470
    (0.62%)
    76.510 USD
    I
    INCY
    -0.680
    (-1.05%)
    64.390 USD
    LLY
    28.47
    (3.54%)
    832.74 USD
    MRK
    0.680
    (0.60%)
    113.800 USD
    REGN
    13.14
    (1.22%)
    1,091.19 USD
الأخبار
المقالات

العنوان: Vanda Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.